|
The use of plasma microRNAs to predict toxicty following liver stereotactic body radiation therapy. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Pi Square LLC |
|
|
Honoraria - Medivation/Astellas (I); Myriad Pharmaceuticals (I) |
Consulting or Advisory Role - GenomeDx (I); Myriad Pharmaceuticals (I); NanoString Technologies (I) |
Speakers' Bureau - Medivation/Astellas (I) |
Research Funding - Celgene (I); Varian Medical Systems (Inst) |
Patents, Royalties, Other Intellectual Property - Patent pending for RadioType Dx, a biomarker test (I) |
Travel, Accommodations, Expenses - GenomeDx (I); Varian Medical Systems |